The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux

Cancer Research

Volumn 61, Issue 2, 2001, Pages 739-748

  Erlichman, Charles ^a   Boerner, Scott A ^a   Hallgren, Christopher G ^a   Spieker, Rebecca ^a   Wang, Xiao Yang ^a   James, C David ^a   Scheffer, George L ^d   Maliepaard, Marc ^e   Ross, Douglas D ^c   Bible, Keith C ^a,b   Kaufmann, Scott H ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CANERTINIB; CELL SURFACE RECEPTOR; IRINOTECAN; PROTEIN TYROSINE KINASE INHIBITOR; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MICROFLUOROMETRY; ONCOGENE NEU; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CAMPTOTHECIN; CELL CYCLE; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; MORPHOLINES; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TOPOTECAN; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; TUMOR STEM CELLS;

EID: 0035863314     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Setting a new standard - Irinotecan (campto) in the second-line therapy of colorectal cancer: Final results of two Phase III studies and implications for clinical practice
2. Topoisomerase 1 inhibitors in the treatment of colorectal cancer
3. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
4. Irinotecan therapy in adults with recurrent or progressive malignant glioma
5. Topoisomerase-I inhibitors in gynecologic tumors
6. Topotecan: A review of its efficacy in small cell lung cancer
7. DNA topoisomerases: Essential enzymes and lethal targets
8. Eukaryotic DNA topoisomerase-I
9. DNA topoisomerases
10. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin
11. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells
12. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials
13. Topoisomerase poisons: Harnessing the dark side of enzyme mechanism
14. The current status of camptothecin analogues as antitumor agents
15. DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways
16. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function
17. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: Elevated dTTP pools and enhanced cytotoxicity
18. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: A cautionary note
19. Camptothecin, teniposide, 4′-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induced degradation of nuclear DNA in the S phase of HL-60 cells
20. Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells
21. Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors
22. Cellular resistance to topoisomerase poisons
23. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
24. Camptothecin overcomes mdrl-mediated resistance in human KB carcinoma cells
25. Effect of p-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue
26. Cross resistance of mdr, p-glycoprotein overexpressing CHO cells to camptothecin analogues
27. Differential cytotoxicity of clinically important camptothecin derivatives in p-glycoprotein-overexpressing cell lines
28. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma celt line is not due to DNA topoisomerase I alterations
29. Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of p-glycoprotein
30. Camptothecin resistance: Role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells
31. The mouse Bcrpl/Mxr/Abcp gene: Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin
32. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines
33. Tyrosine kinase inhibitors 15.4-(phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor
34. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials
35. Epidermal growth factor receptor inhibition in cancer therapy: Biology, rationale, and preliminary clinical results
36. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastoma
37. The HER-2/neu oncogene: Prognostic factor, predictive factor and target for therapy
38. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis
39. The clinical significance of epidermal growth factor (EGF-R) in human breast cancer: A review on 5232 patients
40. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer
41. Prognostic significance of methyl-p-hydroxy-phenyllactate-esterase activity in laryngeal squamous cell carcinoma
42. Therapeutic application of anti-growth factor receptor antibodies
43. Inhibition of the epidermal growth factor receptor family of transferase kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors
44. Tyrosine kinase inhibitors in preclinical development
45. Action of camptothecin on mammalian cells in culture
46. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
47. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells
48. 1arrest in vitro
49. Cultural and antigenic properties of newly established cell strains derived from adenocarcinomas of the human colon and rectum
50. Characterization of camptothecin-resistant Chinese hamster lung cells
51. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines
52. Activation of multiple interleukin-1β converting enzyme homologues in cytosol and nuclei of HL-60 human leukemia cell lines during etoposide-induced apoptosis
53. Selective induction of apoptosis in Hep 3B cells by topoisomerase I inhibitors: Evidence for a protease-dependent pathway that does not activate CPP32
54. Topoisomerase II levels during granulocytic maturation in vitro and in vivo
55. A multidrug resistance transporter from human MCF-7 breast cancer cells
56. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux
57. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
58. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I
59. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line
60. Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells
61. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
62. A one-step method for protein estimation in biological samples: Nitration of tyrosine in nitric acid
63. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: Importance of sequence of administration
64. Elevated DNA polymerase α, DNA polymerase β, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan
65. Changes in topoisomerase I levels and localization during myeloid maturation in vitro and in vivo
66. What is synergy?
67. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells
68. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo
69. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells
70. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes
71. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line
72. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein
73. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR